Disease Domain | Count |
---|---|
Neoplasms | 5 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 5 |
Chemical drugs | 1 |
Target |
Mechanism HIF-1α inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism AIMP2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GSK-3β inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date18 Jul 2024 |
Sponsor / Collaborator |
Start Date01 May 2024 |
Sponsor / Collaborator [+21] |
Start Date23 Feb 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Dehydroeburicoic acid ( GSK-3β ) | Neoplasms More | Preclinical |
Bcl-848 ( AIMP2 ) | Neoplasms More | Preclinical |
LW-1564 ( HIF-1α ) | Neoplasms More | Preclinical |
SYA014 ( σ2 receptor ) | Lung Cancer More | Preclinical |
Dimethyl α-ketoglutarate ( MMPs ) | Wrinkling of skin More | Preclinical |